Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Masahiro Sakagami"'
Autor:
Donald F. Brophy, Rami A. Al-Horani, Masahiro Sakagami, Elsamani I. Abdelfadiel, Erika J. Martin, Daniel K. Afosah, Bassem M. Mohammed, Shravan Morla, Umesh R. Desai, Jyothi C. Sistla
Publikováno v:
J Thromb Haemost
Background Human factor XIa (FXIa) is an actively pursued target for development of safer anticoagulants. Our long-standing hypothesis has been that allosterism originating from heparin-binding site(s) on coagulation enzymes is a promising approach t
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 53:52-60
Emphysema progressively destroys alveolar structures, leading to disability and death, yet remains irreversible and incurable to date. Impaired vascular endothelial growth factor (VEGF) signaling is an emerging pathogenic mechanism, thereby proposing
Autor:
Jayne E. Hastedt, Per Bäckman, Andrew R. Clark, William Doub, Anthony Hickey, Guenther Hochhaus, Phil J. Kuehl, Claus-Michael Lehr, Peter Mauser, Jason McConville, Ralph Niven, Masahiro Sakagami, Jeffry G. Weers
Publikováno v:
AAPS Open, Vol 2, Iss 1, Pp 1-1 (2016)
Externí odkaz:
https://doaj.org/article/6e5951894e0a4f65983b1feb9e14ab9c
Autor:
Masahiro Sakagami
Publikováno v:
Advanced drug delivery reviews.
The assessment and prediction of lung absorption and disposition are an increasingly essential preclinical task for successful discovery and product development of inhaled drugs for both local and systemic delivery. Hence, in vitro, ex vivo and in vi
Autor:
Masahiro Sakagami, Ruba S. Darweesh
Publikováno v:
European Journal of Pharmaceutical Sciences. 115:68-76
As a promising long-acting inhaled formulation, liposomal ciprofloxacin (Lipo-CPFX) was characterized in the in vitro human lung epithelial Calu-3 cell monolayer system, compared to ciprofloxacin in solution (CPFX). Its modulated absorptive transport
In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products
Publikováno v:
Pharmaceutical Research. 36
To establish an in vivo-relevant Transwell dish-based dissolution test system for the “respirable” aerosols of inhaled corticosteroids (ICSs) using marketed inhaler products. “Respirable” ≤ 5.8 or 6.5 μm aerosols of 7 ICSs from 11 inhaler
Autor:
Connor P. O'Hara, Daniel K. Afosah, Masahiro Sakagami, Bhaumik B. Patel, Umesh R. Desai, Shravan Morla, Rio S. Boothello
Publikováno v:
The FASEB Journal. 33
Autor:
Masahiro Sakagami, Matthew S. Halquist, Priya P Nadkarni, Richard M. Costanzo, H. Thomas Karnes
Publikováno v:
Therapeutic Delivery. 6:297-306
Background: Oxyntomodulin (OXM1–37) is an anorectic gut-secreting peptide with a promise to treat obesity, but its needle-free delivery has yet to be successful. Results: Pulmonary delivery of OXM1–37, but not its C-terminal octapeptides, caused
Autor:
Masahiro Sakagami, Harm Jan Bogaard, Peter R. Byron, Norbert F. Voelkel, Shiro Mizuno, Jose Gomez-Arroyo, Donatas Kraskauskas, Antonio Abbate, Benjamin W. Van Tassell, Laszlo Farkas, Aamer Syed
Publikováno v:
Gomez-Arroyo, J, Sakagami, M, Syed, A A, Farkas, L, Van Tassell, B, Kraskauskas, D, Mizuno, S, Abbate, A, Bogaard, H J, Byron, P R & Voelkel, N F 2015, ' Iloprost reverses established fibrosis in experimental right ventricular failure ', European Respiratory Journal, vol. 45, no. 2, pp. 449-462 . https://doi.org/10.1183/09031936.00188013
European Respiratory Journal, 45(2), 449-462. European Respiratory Society
European Respiratory Journal, 45(2), 449-462. European Respiratory Society
Prostacyclin and its analogues improve cardiac output and functional capacity in patients with pulmonary arterial hypertension (PAH); however, the underlying mechanism is not fully understood. We hypothesised that prostanoids have load-independent be
Autor:
Hiroko Togame, Masahiro Sakagami, Yusuke Takeoka, Fumiyo Takahashi, Shuji Yonezawa, Hiroshi Takemoto, Satoshi Ichikawa, Yoshikazu Tanaka, Mitsuaki Sekiguchi, Tetsuya Tanino, Akira Matsuda
Publikováno v:
ACS Medicinal Chemistry Letters. 5:556-560
It is urgent to develop novel anti-Pseudomonas agents that should also be active against multidrug resistant P. aeruginosa. Expanding the antibacterial spectrum of muraymycins toward P. aeruginosa was investigated by the systematic structure-activity